ClinicalTrials.gg
CompletedNCT00419926Updated Mar 1, 2011Results posted

Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients

A Phase 4 interventional study of Enteric-coated mycophenolate sodium (Myfortic) and Cyclosporine (Neoral) in Kidney Transplantation, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-03-01.

Sponsored by Novartis · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine if an initial intensified enteric-coated mycophenolate sodium (Myfortic) dosing regimen administered during the first six weeks post renal transplantation provides improved efficacy, with a similar safety profile, compared to a standard regimen of Myfortic.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Renal, Kidney, Intensified, Enteric-coated mycophenolate sodium, Transplant
03

In context

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, 18 to 65 years old
  • First or second time kidney transplant patients
  • For females capable of becoming pregnant, negative pregnancy test prior to entry into trial and effective during trial and 3 months after stopping trial medication

Exclusion criteria

Exclusion Criteria:

  • Previous graft loss due to immunological reasons in the 1st year after the 1st transplant
  • Multi-organ recipients or previous transplant of another organ, different from the kidney
  • Recipients from a non-heart-beating donor
  • Known to mycophenolic acid or cyclosporine
  • positive or surface antigen positive
  • History of (past 5 years)
  • Pregnancy or planned pregnancy, lactating, or unwillingness to use effective .
  • Evidence of severe liver disease

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    Intensified Mycophenolate Sodium (Myfortic) dosing regimen

    In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.

    Drug: Enteric-coated mycophenolate sodium (Myfortic) · Drug: Cyclosporine (Neoral) · Drug: Prednisone

  • Active comparator
    Standard Mycophenolate Sodium (Myfortic) dosing regimen

    In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.

    Drug: Enteric-coated mycophenolate sodium (Myfortic) · Drug: Cyclosporine (Neoral) · Drug: Prednisone

Interventions

  • 1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.

  • cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels

  • 20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death

    To evaluate therapeutic benefit by comparing the efficacy defined as the number of participants with treatment failure (biopsy-proven acute rejection \[BPAR\], graft loss \[GFL\] or death) at 6 months post-transplant. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)

    Time frame: 6 months

Secondary outcomes

  1. Comparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death

    The overall treatment differences of the number of participants with at least one occurrence of the composite event BPAR, GFL or death at study days 21 and 84 post-transplantation. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)

    Time frame: 21 and 84 days

  2. Renal Function Assessed by Glomerular Filtration Rate (GFR)at Each Visit

    The Modification of Diet in Renal Disease (MDRD) formula was used to calculate the GFR. Serum creatinine levels, age, sex and race were used to estimate the GFR levels in mL/min/1.73m\^2.

    Time frame: at 21 days, 84 days and 180 days

  3. Renal Function Assessed by Serum Creatinine at Each Visits

    Time frame: at 21 days, 84 days and 180 days

07

Results

Posted Jan 11, 2011

Participant flow

Participant flow — Overall Study
MilestoneIntensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
Started155158
Completed141148
Not completed1410
Withdrew: Withdrawal by subject73
Withdrew: Administrative problem44
Withdrew: Lost to follow-up12
Withdrew: Death21

Outcome measures

PrimaryNumber of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death

To evaluate therapeutic benefit by comparing the efficacy defined as the number of participants with treatment failure (biopsy-proven acute rejection \[BPAR\], graft loss \[GFL\] or death) at 6 months post-transplant. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)

Time frame:
6 months
Reported as:
Number · number of participants
Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death
number of participantsIntensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death3336
SecondaryComparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death

The overall treatment differences of the number of participants with at least one occurrence of the composite event BPAR, GFL or death at study days 21 and 84 post-transplantation. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)

Time frame:
21 and 84 days
Reported as:
Number · number of participants
Comparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death
number of participantsIntensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
Day 212021
Day 843334
SecondaryComparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death

The overall treatment differences of the number of participants with at least one occurrence of the composite event BPAR, GFL or death at study days 21 and 84 post-transplantation. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)

Time frame:
21 and 84 days
Reported as:
Number · number of participants
Comparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death
number of participantsIntensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
Day 211420
Day 842633
SecondaryRenal Function Assessed by Glomerular Filtration Rate (GFR)at Each Visit

The Modification of Diet in Renal Disease (MDRD) formula was used to calculate the GFR. Serum creatinine levels, age, sex and race were used to estimate the GFR levels in mL/min/1.73m\^2.

Time frame:
at 21 days, 84 days and 180 days
Reported as:
Mean · (mL/min/1.73m^2)
Renal Function Assessed by Glomerular Filtration Rate (GFR)at Each Visit
(mL/min/1.73m^2)Intensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
At 21 days47.3 ± 20.0546.8 ± 21.00
At 84 days52.1 ± 19.8051.8 ± 20.21
At 180 days53.5 ± 21.0551.3 ± 25.14
SecondaryRenal Function Assessed by Serum Creatinine at Each Visits
Time frame:
at 21 days, 84 days and 180 days
Reported as:
Mean · umol/L

Results for this outcome have not been posted.

PrimaryNumber of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death

To evaluate therapeutic benefit by comparing the efficacy defined as the number of participants with treatment failure (biopsy-proven acute rejection \[BPAR\], graft loss \[GFL\] or death) at 6 months post-transplant. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.)

Time frame:
6 months
Reported as:
Number · number of participants
Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death
number of participantsIntensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death2635

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen—74/150 (49.3%)143/150 (95.3%)
Standard Mycophenolate Sodium (Myfortic) Dosing Regimen—68/154 (44.2%)145/154 (94.2%)
Most frequent serious events
Showing 10 of 131
Most frequent serious events
EventIntensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
Cytomegalovirus infectionInfections and infestations10/15016/154
Urinary tract infectionInfections and infestations9/15011/154
Kidney transplant rejectionImmune system disorders1/1507/154
Complications of transplanted kidneyInjury, poisoning and procedural complications6/1501/154
LymphoceleVascular disorders1/1506/154
Blood creatinine increasedInvestigations5/1505/154
LeukopeniaBlood and lymphatic system disorders4/1500/154
Renal graft lossInjury, poisoning and procedural complications2/1504/154
Atrial fibrillationCardiac disorders3/1500/154
Abdominal painGastrointestinal disorders3/1501/154
Most frequent other events
Showing 10 of 60
Most frequent other events
EventIntensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing Regimen
ConstipationGastrointestinal disorders58/15051/154
HypertensionVascular disorders51/15045/154
Urinary tract infectionInfections and infestations46/15038/154
Oedema peripheralGeneral disorders42/15046/154
NauseaGastrointestinal disorders43/15038/154
DiarrhoeaGastrointestinal disorders40/15027/154
VomitingGastrointestinal disorders29/15041/154
AnaemiaBlood and lymphatic system disorders39/15037/154
Procedural painInjury, poisoning and procedural complications36/15032/154
HypocalcaemiaMetabolism and nutrition disorders12/15027/154

Baseline characteristics

Age, Customized
Age, Customized(participants)Intensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing RegimenTotal
< 50 years100102202
>=50 years5556111
Sex: Female, Male
Sex: Female, Male(Participants)Intensified Mycophenolate Sodium (Myfortic) Dosing RegimenStandard Mycophenolate Sodium (Myfortic) Dosing RegimenTotal
Female5354107
Male102104206
08

Study locations

1 site
  • Novartis
    Basel, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2007
First posted
Jan 9, 2007
Start
Dec 2006
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Jan 11, 2011
Last update
Mar 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00419926
Lead sponsor
Novartis
First posted
Jan 9, 2007
Start date
Dec 2006
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jan 11, 2011
Last update
Mar 1, 2011

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mycophenolic Acid · Cyclosporine

Start the discussion